Prevalence: 3.1 million US adults diagnosed with IBD (1.3% of the population) — CDC / NHIS data
This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer
The most evidence-backed supplements for IBD are omega-3 fatty acids (2-4g EPA+DHA daily, shown to help maintain...
The most evidence-backed supplements for IBD are omega-3 fatty acids (2-4g EPA+DHA daily, shown to help maintain remission in ulcerative colitis), probiotics (particularly VSL#3 with 450 billion CFU, effective for UC remission maintenance), and vitamin D (2000-4000 IU daily, which modulates intestinal immune responses).
Get the free evidence-based Inflammatory Bowel Disease (IBD) guide — delivered in 60 seconds.
No spam. Unsubscribe anytime.
Inflammatory bowel disease encompasses Crohn's disease and ulcerative colitis, chronic conditions characterized by relapsing inflammation of the gastrointestinal tract. IBD affects approximately 3.1 million US adults. Nutritional deficiencies are common, and several supplements have shown promise as adjunctive therapies for maintaining remission and reducing inflammation.
Inflammatory bowel disease (IBD) — Crohn's disease and ulcerative colitis — involves chronic, relapsing inflammation of the gastrointestinal tract driven by dysregulated immune responses to the gut microbiome in genetically susceptible individuals. The pathophysiology centers on disrupted intestinal barrier function, loss of immune tolerance to commensal bacteria, and excessive Th1/Th17 cytokine production (TNF-alpha, IL-12, IL-23). Pharmaceutical management with aminosalicylates, corticosteroids, immunomodulators, and biologics is the standard of care. IBD patients are at significantly elevated risk for nutritional deficiencies — particularly iron, vitamin D, B12, folate, and zinc — due to malabsorption, inflamed mucosa, and dietary restrictions. Supplementation in IBD targets two goals: correcting the deficiencies that are nearly universal in this population, and providing adjunctive anti-inflammatory support. Probiotics have a specific role in ulcerative colitis (but not Crohn's) for maintaining remission. Supplements cannot replace immunosuppressive therapy for active disease.
Vitamin D plays a significant immunomodulatory role in IBD. Jorgensen et al. (2010) randomized 94 Crohn's patients in remission to 1,200 IU vitamin D3 daily or placebo and found a trend toward reduced relapse (13% versus 29%, p=0.06). Sharifi et al. (2019) found that 50,000 IU vitamin D weekly for 12 weeks in UC patients significantly reduced disease activity scores and inflammatory markers. A meta-analysis by Li et al. (2018) of 18 observational studies found that low vitamin D levels were significantly associated with increased disease activity and higher rates of clinical relapse in both Crohn's and UC. Probiotics have condition-specific evidence. For ulcerative colitis, the VSL#3 formulation (now marketed as Visbiome, containing 8 strains at 450–900 billion CFU) was shown by Sood et al. (2009) to induce remission in 42.9% of active mild-to-moderate UC patients versus 15.7% for placebo. Tursi et al. (2010) confirmed that VSL#3 reduced UCDAI scores significantly. For pouchitis after colectomy, Gionchetti et al. (2000) showed VSL#3 maintained remission in 85% versus 6% on placebo — one of the strongest probiotic trial results ever published. However, for Crohn's disease, probiotic evidence is disappointing — a Cochrane review by Rolfe et al. (2006) found no significant benefit. Omega-3 fatty acids address the inflammatory component. Belluzzi et al. (1996) found that enteric-coated omega-3 (2.7 g daily) reduced relapse rates in Crohn's disease from 74% to 28% over one year. However, the large EPIC trials (Feagan et al., 2008) failed to replicate this benefit, leaving the evidence mixed. Curcumin showed promise as adjunctive therapy in UC — Hanai et al. (2006) randomized 89 UC patients already on mesalamine to curcumin (1 g twice daily) or placebo and found a relapse rate of 4.7% versus 20.5% over 6 months.
For vitamin D, check baseline 25(OH)D levels and aim for 40–60 ng/mL — a higher target than the general population due to the immunomodulatory benefits. Many IBD patients require 4,000–10,000 IU D3 daily, guided by blood monitoring. For probiotics in UC, choose products providing the same multi-strain combination studied in trials: Visbiome (formerly VSL#3) at 450–900 billion CFU daily, or comparable high-dose multi-strain formulations. Single-strain or low-dose probiotics have not shown the same UC benefits. For curcumin, bioavailable forms (Meriva, Theracurmin) at 1,000–2,000 mg daily are used adjunctively for UC, taken alongside standard mesalamine therapy. For omega-3, enteric-coated formulations at 2–4 g EPA+DHA daily may reduce GI irritation. Iron supplementation is critical in IBD — choose iron bisglycinate for better tolerability, or IV iron for severe deficiency where oral iron worsens GI symptoms. All supplementation in IBD should be coordinated with a gastroenterologist.
Aloe vera juice, despite widespread use among IBD patients, has no convincing evidence for Crohn's or UC beyond one small pilot study (Langmead et al., 2004) with 44 UC patients showing a modest trend. Glutamine supplements are sometimes recommended for "leaky gut" in IBD, but a Cochrane review found insufficient evidence to support glutamine for inducing remission in Crohn's disease. Boswellia (frankincense) extract showed some promise in early German studies for UC, but the evidence base is too small and inconsistent for a clinical recommendation. Slippery elm, marshmallow root, and other demulcent herbs are popular in alternative medicine for IBD but have never been tested in rigorous RCTs. Cannabis/CBD products have enormous anecdotal support among IBD patients but clinical trial data is limited to small, short-term studies with mixed results — a 2018 Cochrane review found insufficient evidence to draw conclusions about cannabis for IBD.
For IBD maintenance support (in addition to prescribed therapy): vitamin D3 (4,000–5,000 IU daily, targeting 40–60 ng/mL by blood test), a high-dose multi-strain probiotic like Visbiome (450 billion CFU daily, evidence strongest for UC), omega-3 fish oil (2–3 g EPA+DHA daily, enteric-coated), and curcumin (1 g enhanced form twice daily, strongest evidence for UC adjunctive maintenance). Add iron bisglycinate if ferritin is low and B12 (methylcobalamin 1,000 mcg sublingual) if on methotrexate or with ileal disease. These supplements complement — never replace — gastroenterologist-directed immunosuppressive therapy. Monitor vitamin D, B12, iron, and folate levels quarterly. See /stacks/immune-resilience for overlapping immune-modulation principles.
IBD (Crohns disease and ulcerative colitis) is a chronic inflammatory condition that requires physician-managed care; supplements are adjuncts during remission and never a replacement for induction therapy during a flare. Seek urgent care for severe abdominal pain with fever, heavy or persistent bloody diarrhea, signs of dehydration, fainting, a rigid or distended abdomen (possible toxic megacolon or perforation), new extra-intestinal symptoms (uveitis, joint pain with rash), or inability to keep fluids down. Book same-week gastroenterology for any new bloody stool, persistent diarrhea beyond three weeks, perianal fistulas or abscesses, weight loss over 10%, or a planned pregnancy while on biologics. Standard-of-care therapy (aminosalicylates, corticosteroids, immunomodulators, biologics) is first-line; omega-3s, curcumin, VSL-3 probiotics, and vitamin D are evaluated as adjuncts.
| # | Supplement | Typical Dose | Evidence | |
|---|---|---|---|---|
| 1 | Omega-3 Fatty Acids | 2-4g EPA+DHA daily | Moderate | |
| See top omega-3 fatty acids picks → | ||||
| 2 | Probiotics (VSL#3 / Multi-strain) | 450 billion CFU daily (VSL#3) or equivalent multi-strain | Strong | |
| See top probiotics (vsl#3 / multi-strain) picks → | ||||
| 3 | Turmeric / Curcumin | 1g curcumin twice daily | Moderate | |
| See top turmeric / curcumin picks → | ||||
| 4 | Vitamin D | 2000-4000 IU daily | Moderate | |
| See top vitamin d picks → | ||||
| 5 | L-Glutamine | 5-15g daily in divided doses | Emerging | |
| See l-glutamine research → | ||||
As an Amazon Associate, we earn from qualifying purchases. Some links below are affiliate links — this doesn't affect our editorial independence or product ratings. How we evaluate products
Sports Research Triple Strength Omega-3
Sports Research
Seed PDS-08 Pediatric Daily Synbiotic
Seed
Peak Performance Theracurmin
Peak Performance
NatureWise Vitamin D3 5000 IU
NatureWise
Probiotics, particularly the multi-strain formulation VSL#3 (containing 450 billion CFU of 8 bacterial strains), have the strongest evidence for ulcerative colitis. A systematic review with meta-analysis of 22 RCTs found VSL#3 effective for inducing remission in active UC and probiotics equivalent to 5-ASAs for preventing relapse [1]. Evidence for probiotics in Crohn's disease is less consistent. Strain and dose matter significantly — generic probiotics may not provide the same benefits.
Evidence:Meta-analysis (2017) · 22 RCTs · moderate confidence[#1]. See full reference list below.Yes. A pivotal RCT published in Clinical Gastroenterology and Hepatology found that adding 1g of curcumin twice daily to mesalamine therapy maintained remission in 95% of ulcerative colitis patients over 6 months, compared to 79% with mesalamine alone. Curcumin inhibits NF-κB and multiple inflammatory pathways active in IBD. It should be used as an adjunct to, not replacement for, prescribed IBD medications.
Vitamin D deficiency affects 30-40% of IBD patients due to intestinal malabsorption, reduced sun exposure during flares, and chronic inflammation that depletes vitamin D stores. Vitamin D regulates tight junction proteins in the gut lining and modulates Th17/Treg immune cell balance. An RCT in Crohn's patients found high-dose vitamin D supplementation reduced relapse risk.
Glutamine is the primary fuel source for enterocytes (intestinal lining cells) and supports intestinal barrier integrity. Clinical studies show glutamine supplementation (5-15g daily) can reduce intestinal permeability, a hallmark of IBD. While results are promising, particularly for post-surgical IBD patients, more large-scale RCTs are needed to establish firm dosing recommendations for IBD specifically.
Omega-3 fatty acids (EPA + DHA) reduce inflammation, support heart and brain health, and may improve mood. The REDUCE-IT trial showed high-dose EPA (4g/day) reduced cardiovascular events by 25%. Most adults benefit from 1,000-2,000mg combined EPA+DHA daily.
Product Comparison